Top Markets
Coin of the day
Abbott Laboratories Abbott Laboratories

Abbott Laboratories

ABT
Clasificación en acciones #84
Abbott Laboratories, together with its subsidiaries, discovers, develops,... Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Precio por acción
$101.91
Capitalización bursátil
$177.09B
Cambio (1 día)
-1.97%
Cambio (1 año)
-19.78%
País
US
Comercio Abbott Laboratories (ABT)

Categoría

Ratio P/E de Abbott Laboratories (ABT)
Ratio P/E al April 2026 TTM: 27.47
Según los últimos informes financieros y el precio de las acciones de Abbott Laboratories, el P/E actual (TTM) de la empresa es 27.47. Al final de 2024, la empresa tenía un P/E de 14.62.
Historial del ratio P/E de Abbott Laboratories desde 2000 hasta 2026
Relación P/E al final de cada año
Año Ratio P/E Cambiar
2026 (TTM) 27.47 -18.12%
2025 33.55 129.56%
2024 14.62 -56.18%
2023 33.35 20.14%
2022 27.76 -21.42%
2021 35.33 -18.19%
2020 43.19 3.69%
2019 41.65 -22.33%
2018 53.63 -74.29%
2017 208.61 416.25%
2016 40.41 170.24%
2015 14.95 -49.70%
2014 29.72 29.04%
2013 23.04 177.98%
2012 8.29 -7.25%
2011 8.93 16.57%
2010 7.66 10.25%
2009 6.95 -13.90%
2008 8.07 -29.75%
2007 11.49 -44.65%
2006 20.76 139.13%
2005 8.68 -19.34%
2004 10.76 -9.48%
2003 11.89 18.37%
2002 10.05 -59.93%
2001 25.07 107.16%
2000 12.10 0.00%
Relación P/E para empresas similares o competidores
Empresa P/E Ratio Diferencia del P/E Ratio País
38.72 40.95%
US
24.08 -12.35%
IE
24.08 -12.35%
IE
32.19 17.19%
US
19.12 -30.39%
DE
¿Cómo leer un P/E ratio?

El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.

Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.

Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.